



## Clinical trial results:

### A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

#### Summary

EudraCT number	2020-004782-39
Trial protocol	FR BE IT ES
Global end of trial date	

#### Results information

Result version number	v1 (current)
This version publication date	23 February 2024
First version publication date	23 February 2024

#### Trial information

##### Trial identification

Sponsor protocol code	DS8201-A-U207
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04744831
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Daiichi Sankyo, Inc.
Sponsor organisation address	211 Mt Airy Rd, Basking Ridge, United States, 07920
Public contact	Medical Director, Daiichi Sankyo Inc., 1 9089927876, CTRInfo@dsi.com
Scientific contact	Medical Director, Daiichi Sankyo Inc., 1 9089927876, CTRInfo@dsi.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	31 October 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 October 2022
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

This study evaluates the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC)

Protection of trial subjects:

This study was conducted in compliance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the International Council for Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) (CPMP/ICH/135/95), and applicable regulatory requirement(s), including the following:

European Commission Directive (2001/20/EC Apr 2001) and/or

European Commission Directive (2005/28/EC Apr 2005) and/or

United States (US) Food and Drug Administration (FDA) GCP Regulations: Code of Federal Regulations Title 21, parts 11, 50, 54, 56 and 312 as appropriate and/or Japanese Ministry of Health, Labor and Welfare Ordinance No. 28 (27 March 1997) and/or

The Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics No. 1 (25 November 2014) and/or

Other applicable local regulations

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 March 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 14
Country: Number of subjects enrolled	Japan: 43
Country: Number of subjects enrolled	France: 8
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	United States: 8
Country: Number of subjects enrolled	Australia: 8
Country: Number of subjects enrolled	Italy: 19
Country: Number of subjects enrolled	Taiwan: 6
Country: Number of subjects enrolled	Belgium: 12
Worldwide total number of subjects	122
EEA total number of subjects	43

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	77
From 65 to 84 years	45
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 122 subjects who met all inclusion criteria and no exclusion criteria were randomized/registered to T-DXd treatment in 46 clinical sites, US = 4; Australia = 5; Belgium = 3; France = 5; Italy = 4; Japan = 10; South Korea = 6; Spain = 4, Taiwan = 4, and United Kingdom = 1.

### Pre-assignment

Screening details:

Following adequate study explanation by the investigator or their designee, subjects voluntarily offered signed, informed consent prior to participation in any study procedures.

### Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Stage 1: T-DXd 5.4 mg/kg Q3W

Arm description:

Participants were randomized/registered to receive an intravenous (IV) infusion of T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).

Arm type	Experimental
Investigational medicinal product name	Trastuzumab deruxtecan
Investigational medicinal product code	
Other name	Trastuzumab deruxtecan, T-DXd, DS-8201a
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous (IV) infusion administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).

<b>Arm title</b>	Stage 2: T-DXd 5.4 mg/kg Q3W
------------------	------------------------------

Arm description:

Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 5.4 mg/kg Q3W.

Arm type	Experimental
Investigational medicinal product name	Trastuzumab deruxtecan
Investigational medicinal product code	
Other name	Trastuzumab deruxtecan, T-DXd, DS-8201a
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous (IV) infusion administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).

<b>Arm title</b>	Stage 1: T-DXd 6.4 mg/kg Q3W
------------------	------------------------------

Arm description:

Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 6.4 mg/kg Q3W.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Trastuzumab deruxtecan
Investigational medicinal product code	
Other name	Trastuzumab deruxtecan, T-DXd, DS-8201a
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous (IV) infusion administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).

<b>Number of subjects in period 1</b>	Stage 1: T-DXd 5.4 mg/kg Q3W	Stage 2: T-DXd 5.4 mg/kg Q3W	Stage 1: T-DXd 6.4 mg/kg Q3W
Started	40	42	40
Completed	3	6	5
Not completed	37	36	35
Adverse event, serious fatal	-	2	1
Adverse event, non-fatal	3	3	3
Progressive Disease	31	27	25
Not Specified	-	2	1
Clinical Progression	3	2	5

## Baseline characteristics

### Reporting groups

Reporting group title	Stage 1: T-DXd 5.4 mg/kg Q3W
Reporting group description:	
Participants were randomized/registered to receive an intravenous (IV) infusion of T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).	
Reporting group title	Stage 2: T-DXd 5.4 mg/kg Q3W
Reporting group description:	
Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 5.4 mg/kg Q3W.	
Reporting group title	Stage 1: T-DXd 6.4 mg/kg Q3W
Reporting group description:	
Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 6.4 mg/kg Q3W.	

Reporting group values	Stage 1: T-DXd 5.4 mg/kg Q3W	Stage 2: T-DXd 5.4 mg/kg Q3W	Stage 1: T-DXd 6.4 mg/kg Q3W
Number of subjects	40	42	40
Age categorical			
Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days - 23 months)	0	0	0
Children (2 - 11 years)	0	0	0
12 - 17 years	0	0	0
Adults (18 - 64 years)	29	25	23
From 65 - 84 years	11	17	17
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Male	21	24	19
Female	19	18	21

Reporting group values	Total		
Number of subjects	122		
Age categorical			
Units: Subjects			
In Utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days - 23 months)	0		
Children (2 - 11 years)	0		
12 - 17 years	0		
Adults (18 - 64 years)	77		
From 65 - 84 years	45		
85 years and over	0		

Gender categorical			
Units: Subjects			
Male	64		
Female	58		

## End points

### End points reporting groups

Reporting group title	Stage 1: T-DXd 5.4 mg/kg Q3W
Reporting group description: Participants were randomized/registered to receive an intravenous (IV) infusion of T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).	
Reporting group title	Stage 2: T-DXd 5.4 mg/kg Q3W
Reporting group description: Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 5.4 mg/kg Q3W.	
Reporting group title	Stage 1: T-DXd 6.4 mg/kg Q3W
Reporting group description: Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 6.4 mg/kg Q3W.	

### Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer

End point title	Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer <sup>[1]</sup>
End point description: Confirmed objective response rate (ORR), defined as the number (percentage) of participants with complete response (CR) or partial response (PR), were assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.	
End point type	Primary
End point timeframe: 6 months post-dose administration to data cut off, up to 20 months	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: ORR was summarized with 95% Confidence Interval based on the Clopper-Pearson method for single proportion.

End point values	Stage 1: T-DXd 5.4 mg/kg Q3W	Stage 2: T-DXd 5.4 mg/kg Q3W	Stage 1: T-DXd 6.4 mg/kg Q3W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	40	42	40	
Units: percentage of participants				
number (confidence interval 95%)	45.0 (29.3 to 61.5)	31.0 (17.6 to 47.1)	27.5 (14.6 to 43.9)	

## Statistical analyses





## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up to 20 months. For Primary Results, data was collected up until November 01, 2022.

Adverse event reporting additional description:

Safety parameters were collected, analyzed, and reported based on the dosage of treatment drug administered as specified in the study protocol, therefore as 2 arms, T-DXd 5.4 mg/kg Q3W and T-DXd 6.4 mg/kg Q3W.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	T-DXd 6.4 mg/kg Q3W
-----------------------	---------------------

Reporting group description:

Participants were randomized/registered to receive an IV infusion of T-DXd administered at a dose of 6.4 mg/kg Q3W.

Reporting group title	T-DXd 5.4 mg/kg Q3W
-----------------------	---------------------

Reporting group description:

Participants were randomized/registered to receive an intravenous (IV) infusion of T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).

Serious adverse events	T-DXd 6.4 mg/kg Q3W	T-DXd 5.4 mg/kg Q3W	
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 39 (30.77%)	20 / 83 (24.10%)	
number of deaths (all causes)	13	26	
number of deaths resulting from adverse events	1	2	
Investigations			
Neutrophil count decreased			
subjects affected / exposed	2 / 39 (5.13%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	1 / 39 (2.56%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	1 / 1	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Inferior vena cava syndrome			

subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Hepatic encephalopathy			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 39 (2.56%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 39 (2.56%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 39 (2.56%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	1 / 1	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	

Asthenia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 39 (0.00%)	3 / 83 (3.61%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 39 (2.56%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 39 (0.00%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal perforation			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ileus paralytic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	1 / 39 (2.56%)	0 / 83 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatobiliary disorders			
Hepatic failure			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	1 / 1	
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 39 (2.56%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 39 (2.56%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	

Musculoskeletal and connective tissue disorders			
Sacral pain			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 39 (0.00%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	0 / 39 (0.00%)	2 / 83 (2.41%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Candida infection			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Anal abscess			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoalbuminaemia			
subjects affected / exposed	0 / 39 (0.00%)	1 / 83 (1.20%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	T-DXd 6.4 mg/kg Q3W	T-DXd 5.4 mg/kg Q3W	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	38 / 39 (97.44%)	80 / 83 (96.39%)	
Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 39 (5.13%)	1 / 83 (1.20%)	
occurrences (all)	2	1	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 39 (15.38%)	17 / 83 (20.48%)	
occurrences (all)	17	28	
Fatigue			
subjects affected / exposed	6 / 39 (15.38%)	16 / 83 (19.28%)	
occurrences (all)	9	35	
Pyrexia			
subjects affected / exposed	4 / 39 (10.26%)	13 / 83 (15.66%)	
occurrences (all)	8	19	
Malaise			

subjects affected / exposed	5 / 39 (12.82%)	4 / 83 (4.82%)	
occurrences (all)	5	5	
Mucosal inflammation			
subjects affected / exposed	2 / 39 (5.13%)	4 / 83 (4.82%)	
occurrences (all)	2	4	
Oedema peripheral			
subjects affected / exposed	6 / 39 (15.38%)	4 / 83 (4.82%)	
occurrences (all)	7	4	
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	5 / 39 (12.82%)	4 / 83 (4.82%)	
occurrences (all)	6	4	
Dyspnoea			
subjects affected / exposed	2 / 39 (5.13%)	6 / 83 (7.23%)	
occurrences (all)	2	7	
Cough			
subjects affected / exposed	2 / 39 (5.13%)	8 / 83 (9.64%)	
occurrences (all)	3	10	
Epistaxis			
subjects affected / exposed	3 / 39 (7.69%)	6 / 83 (7.23%)	
occurrences (all)	5	8	
Investigations			
Neutrophil count decreased			
subjects affected / exposed	17 / 39 (43.59%)	18 / 83 (21.69%)	
occurrences (all)	50	35	
Weight decreased			
subjects affected / exposed	2 / 39 (5.13%)	3 / 83 (3.61%)	
occurrences (all)	2	3	
Lymphocyte count decreased			
subjects affected / exposed	3 / 39 (7.69%)	3 / 83 (3.61%)	
occurrences (all)	4	7	
Blood bilirubin increased			
subjects affected / exposed	5 / 39 (12.82%)	3 / 83 (3.61%)	
occurrences (all)	12	5	
Blood creatinine increased			



subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 3	4 / 83 (4.82%) 4	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 8	8 / 83 (9.64%) 13	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 9	9 / 83 (10.84%) 11	
White blood cell count decreased subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 18	10 / 83 (12.05%) 27	
Platelet count decreased subjects affected / exposed occurrences (all)	12 / 39 (30.77%) 25	17 / 83 (20.48%) 40	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 4	2 / 83 (2.41%) 3	
Nervous system disorders Dysgeusia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	1 / 83 (1.20%) 1	
Dizziness subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	3 / 83 (3.61%) 3	
Headache subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	8 / 83 (9.64%) 10	
Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 2	7 / 83 (8.43%) 13	
Anaemia subjects affected / exposed occurrences (all)	16 / 39 (41.03%) 42	22 / 83 (26.51%) 47	
Eye disorders			

Retinal haemorrhage subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 83 (0.00%) 0	
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	22 / 39 (56.41%) 32	48 / 83 (57.83%) 101	
Stomatitis subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 13	10 / 83 (12.05%) 15	
Vomiting subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4	16 / 83 (19.28%) 28	
Diarrhoea subjects affected / exposed occurrences (all)	11 / 39 (28.21%) 14	19 / 83 (22.89%) 37	
Constipation subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 7	20 / 83 (24.10%) 20	
Abdominal pain subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 4	6 / 83 (7.23%) 7	
Dyspepsia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	3 / 83 (3.61%) 3	
Hepatobiliary disorders			
Hepatic function abnormal subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 4	1 / 83 (1.20%) 1	
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	11 / 39 (28.21%) 12	20 / 83 (24.10%) 23	
Musculoskeletal and connective tissue disorders			
Back pain			

subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	5 / 83 (6.02%) 5	
Infections and infestations			
Pneumonia			
subjects affected / exposed	2 / 39 (5.13%)	0 / 83 (0.00%)	
occurrences (all)	2	0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 39 (5.13%)	2 / 83 (2.41%)	
occurrences (all)	2	2	
Urinary tract infection			
subjects affected / exposed	2 / 39 (5.13%)	3 / 83 (3.61%)	
occurrences (all)	2	4	
COVID-19			
subjects affected / exposed	5 / 39 (12.82%)	13 / 83 (15.66%)	
occurrences (all)	5	13	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	6 / 39 (15.38%)	25 / 83 (30.12%)	
occurrences (all)	9	40	
Hypokalaemia			
subjects affected / exposed	4 / 39 (10.26%)	6 / 83 (7.23%)	
occurrences (all)	5	8	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported